Ed DeVaney Named PCMA Board Chair
The CVS Caremark executive has succeeded Adam Kautzner as the new chair of the pharmacy trade group.
Updated on Sept. 21, 2026 in People
Live Poll
Do you trust that pharmacy benefit managers effectively lower prescription drug costs for your household?
Ed DeVaney has been appointed as the new Chair of the Board of Directors for the Pharmaceutical Care Management Association (PCMA). He succeeds Adam Kautzner, who recently concluded his term in the leadership role.
Why it matters
The board leadership transition at the Washington-based organization comes as the pharmacy benefit management industry continues to navigate significant regulatory and public scrutiny. The appointment places a key CVS Caremark executive at the helm of the industry's primary advocacy group.
Ed DeVaney brings over 25 years of professional experience in health care and pharmacy benefit management to the board position. The transition was finalized upon the completion of Adam Kautzner's service.
The players
Ed DeVaney
He is the current Executive Vice President and President of CVS Caremark who has spent over 25 years working in the pharmacy benefit management sector.
Adam Kautzner
He is the President of Evernorth Care Management and Express Scripts Evernorth Health Services who previously served as the PCMA Board Chair.
David Marin
He serves as the President and CEO of the Pharmaceutical Care Management Association based in Washington, D.C.
The details
DeVaney currently serves as the Executive Vice President and President of CVS Caremark. He will oversee the PCMA board in Washington, D.C., working alongside organization leadership, including President and CEO David Marin.
Timeline
The announcement naming Ed DeVaney as the new PCMA Board Chair was released on September 21, 2026.
Market Landscape
This leadership transition signals a consolidation of influence for major pharmacy benefit managers within the Pharmaceutical Care Management Association. The move positions the organization to maintain its advocacy posture during a period of intense sector oversight.
Changes in board leadership at trade organizations often precede shifts in public policy advocacy and lobbying priorities. Patients may not see immediate changes, but these executive roles influence the long-term regulatory environment for pharmacy benefits.
The takeaway
The appointment reflects the continued influence of major pharmacy benefit managers in steering industry-wide advocacy efforts. Industry participants should monitor upcoming policy statements to identify potential shifts in the group's legislative strategy.
Further reading
For more information on industry leadership shifts, visit the People section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmacy benefit managers effectively lower prescription drug costs for your household?
